4/5
08:03 am
achl
Achilles Therapeutics plc (NASDAQ: ACHL) had its price target lowered by analysts at Chardan Capital from $11.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Achilles Therapeutics plc (NASDAQ: ACHL) had its price target lowered by analysts at Chardan Capital from $11.00 to $6.00. They now have a "buy" rating on the stock.
4/5
07:25 am
achl
Achilles Therapeutics plc (NASDAQ: ACHL) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $8.00.
Medium
Report
Achilles Therapeutics plc (NASDAQ: ACHL) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $8.00.
4/4
06:51 am
achl
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Low
Report
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
4/4
06:45 am
achl
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
High
Report
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
4/4
06:34 am
achl
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning [Yahoo! Finance]
High
Report
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning [Yahoo! Finance]
4/4
06:30 am
achl
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
High
Report
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
2/5
07:00 am
achl
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Medium
Report
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference